U.S. Markets close in 5 hrs 43 mins

  • S&P 500

    3,924.17
    -24.55 (-0.62%)
     

  • Dow 30

    31,892.85
    -212.40 (-0.66%)
     

  • Nasdaq

    11,714.20
    -73.20 (-0.62%)
     

  • Russell 2000

    1,704.88
    -15.42 (-0.90%)
     

  • Crude Oil

    68.81
    -1.15 (-1.64%)
     

  • Gold

    1,994.20
    -1.70 (-0.09%)
     

  • Silver

    23.41
    +0.15 (+0.66%)
     

  • EUR/USD

    1.0761
    -0.0076 (-0.6995%)
     

  • 10-Yr Bond

    3.3690
    -0.0370 (-1.09%)
     

  • Vix

    24.03
    +1.42 (+6.28%)
     

  • GBP/USD

    1.2226
    -0.0062 (-0.5074%)
     

  • USD/JPY

    130.4230
    -0.3660 (-0.2798%)
     

  • BTC-USD

    28,208.21
    +744.05 (+2.71%)
     

  • CMC Crypto 200

    613.24
    -5.15 (-0.83%)
     

  • FTSE 100

    7,401.33
    -98.27 (-1.31%)
     

  • Nikkei 225

    27,385.25
    -34.36 (-0.13%)
     

Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023

Celldex Therapeutics, Inc.
·2 min read
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.

Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET

HAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas. Abstracts will be available on the meeting website today, February 3, 2023.

Presentation Details:

Session Date & Time: Sunday, February 26th at 9:45 am - 10:45 am CT (10:45 am ET – 11:45 am ET)
Poster No. 308: Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria
Presenting Author: Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin

Data included in the abstract are through May 2022. New data will be presented at the AAAAI meeting and will include the following:

  • Data through 24 weeks for Cohorts 1-3 (0.5, 1.5 and 3.0 mg/kg doses)

  • Data through 20 weeks for Cohort 4 (4.5 mg/kg dose); 6 of 9 patients available at this timepoint as of the data cut-off date

Webcast and Conference Call
The Company will host a webcast presentation of the data on Sunday, February 26th at 4:00 pm CT (5:00 pm ET). The event will be webcast live and can be accessed by going to the "Events & Presentations” page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com


Recommended Stories